Strategic partnerships APS has a history of collaboration with biotechnology leaders (example: Recombinetics partnership) and emphasizes fast, tailored GLP compliant studies, presenting an opportunity to position NAMSA as a continuation or expansion partner for gene editing and device-biocompatibility programs.

Regulatory credibility With AAALAC, ISO17025, USDA registration and GLP compliance, APS appeals to risk-averse clients seeking robust preclinical validation for medical devices and pharmaceuticals, suggesting cross-sell potential into NAMSA’s broader CRO offerings for end-to-end regulatory support.

Elite expertise A specialized preclinical center focused on ISO10993, GMP-like biocompatibility testing, toxicology and interventional studies signals demand among medtech startups and established players pursuing accelerated timelines and reliable study design from quote to implementation.

Global standards Recognition such as Global 3Rs Award highlights a commitment to ethical, efficient preclinical practices, which can be leveraged to attract clients prioritizing sustainable and humane research, aligning with NAMSA’s ethical and scientific standards.

Growth potential Revenue in the mid-range and a compact team size position APS for scalable collaborations, cross-sell opportunities into NAMSA’s larger network, and expansion into additional therapeutic areas or increased workflow capacity for faster turnarounds.